Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-7.49 Insider Own0.60% Shs Outstand56.09M Perf Week-1.41%
Market Cap314.10M Forward P/E- EPS next Y-5.80 Insider Trans-3.72% Shs Float53.05M Perf Month-51.60%
Income-396.00M PEG- EPS next Q-1.84 Inst Own- Short Float21.09% Perf Quarter-67.19%
Sales119.20M P/S2.64 EPS this Y-80.50% Inst Trans7.87% Short Ratio4.15 Perf Half Y-78.03%
Book/sh-0.57 P/B- EPS next Y22.40% ROA-49.10% Target Price22.55 Perf Year-83.94%
Cash/sh5.63 P/C0.99 EPS next 5Y36.60% ROE-372.70% 52W Range4.98 - 37.27 Perf YTD-68.82%
Dividend- P/FCF- EPS past 5Y-19.10% ROI-50.10% 52W High-84.97% Beta1.87
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin79.20% 52W Low12.45% ATR0.78
Employees468 Current Ratio3.60 Sales Q/Q38.70% Oper. Margin- RSI (14)23.95 Volatility8.17% 9.07%
OptionableYes Debt/Eq- EPS Q/Q-17.20% Profit Margin- Rel Volume2.03 Prev Close5.20
ShortableYes LT Debt/Eq- EarningsAug 01 BMO Payout- Avg Volume2.70M Price5.60
Recom2.40 SMA20-36.60% SMA50-52.62% SMA200-70.28% Volume5,473,927 Change7.69%
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
Aug-13-19 10:58AM  AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis Benzinga
Aug-08-19 11:56PM  3 Stocks That Are Absurdly Cheap Right Now Motley Fool -35.01%
06:26PM  Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes Business Wire
Aug-07-19 04:10PM  Clovis Oncology to Offer $225 Million of Convertible Senior Notes Business Wire
Aug-06-19 07:58PM  Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.32%
Aug-02-19 10:04AM  Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down Zacks
06:24AM  Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 01:11PM  Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today Motley Fool -15.92%
Jul-25-19 10:33AM  Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-24-19 09:00AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-18-19 08:00AM  Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1 Business Wire -6.16%
Jul-16-19 10:51AM  Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study Zacks
Jul-12-19 03:18PM  Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price? Simply Wall St.
Jul-02-19 08:37AM  Do Options Traders Know Something About Clovis (CLVS) Stock We Don't? Zacks -5.99%
Jun-24-19 08:33AM  Pfizer's Talzenna Gets Approval in Europe for Breast Cancer Zacks -11.30%
Jun-18-19 08:59AM  AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use Zacks
Jun-13-19 11:51AM  Is Clovis Oncology Inc (CLVS) A Good Stock To Buy? Insider Monkey
Jun-07-19 07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 04:05PM  Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair Business Wire
09:31AM  Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report? Zacks
Jun-01-19 07:30AM  Expanded Rubraca® (Rucaparib) Data from Clovis Oncologys ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting Business Wire
May-29-19 04:23PM  Biotech Stocks Clobbered As Two Slammed With Sell Ratings Investor's Business Daily
10:08AM  Clovis Oncology Stock Sinks on Dim View of Cancer Drug Sales Barrons.com
May-20-19 04:05PM  Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca® in Advanced Ovarian Cancer Business Wire
May-16-19 08:00AM  Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting Business Wire
May-15-19 10:40PM  Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-08-19 09:46AM  Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks
05:23AM  Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 09:15AM  Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:09AM  Clovis: 1Q Earnings Snapshot Associated Press
08:00AM  Clovis Oncology Announces First Quarter 2019 Operating Results Business Wire
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
03:06PM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
11:42AM  Cronos (CRON) to Report Q1 Earnings: What's in the Cards? Zacks
08:00AM  Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019 Business Wire
May-03-19 10:12AM  Heres What Hedge Funds Think About About Clovis Oncology Inc (CLVS) Insider Monkey
May-02-19 08:00AM  Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million Business Wire
Apr-30-19 10:32AM  Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-25-19 02:58PM  What Are Analysts Saying About The Future Of Clovis Oncology, Inc.'s (NASDAQ:CLVS)? Simply Wall St.
Apr-24-19 04:05PM  Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7 Business Wire
Apr-18-19 11:29AM  Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks
Apr-16-19 10:38AM  Company News For Apr 16, 2019 Zacks
Apr-15-19 04:37PM  Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment InvestorPlace -12.48%
03:31PM  Here's Why Clovis Oncology Stock Dropped as Much as 13% Today Motley Fool
12:36PM  Analysts, Options Traders Swarm Sinking CLVS Stock Schaeffer's Investment Research
09:57AM  Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks
Apr-12-19 06:02PM  Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report MarketWatch
05:46PM  Clovis Oncology, Conduent, Edison International and More: Heres What The Smart Money Thinks of These Market Movers Insider Monkey
05:37PM  Clovis Oncology halts mid-stage bladder cancer trial, shares drop Reuters
Apr-10-19 10:14AM  AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks
Apr-03-19 10:22AM  Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks
Apr-02-19 09:44AM  Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks
08:30AM  Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019 Business Wire
Apr-01-19 08:44AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks
Mar-28-19 09:30AM  Why Is Clovis (CLVS) Down 21% Since Last Earnings Report? Zacks
Mar-19-19 08:00AM  Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting Business Wire
Mar-16-19 12:45PM  Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress Business Wire
Mar-07-19 02:07PM  Did Changing Sentiment Drive Clovis Oncologys Share Price Down A Worrying 66%? Simply Wall St.
Mar-06-19 04:19PM  Clovis Oncology to Present at the Barclays Global Healthcare Conference Business Wire -5.31%
07:00AM  New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-04-19 03:00AM  Clovis Oncology Announces Availability of Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany Business Wire
Mar-01-19 06:39AM  Edited Transcript of CLVS earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 05:43PM  Here's Why Clovis Oncology Stock Jumped on Wednesday Motley Fool +13.17%
08:12AM  Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover Zacks
07:15AM  AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study Zacks
12:46AM  Clovis Oncology Inc (CLVS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 08:00AM  Clovis Oncology Announces 2018 Operating Results Business Wire
06:30AM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-19 08:00AM  Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference Business Wire
Feb-21-19 09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
08:40AM  Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks
Feb-19-19 07:00AM  Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies PR Newswire
Feb-13-19 07:30AM  New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-12-19 08:00AM  Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26 Business Wire
Jan-28-19 07:02AM  Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe Zacks
Jan-24-19 01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
12:28PM  Clovis Oncology Announces European Commission Authorization of Rubraca® (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer Business Wire
Jan-18-19 06:41AM  Immunomedics Gets CRL From FDA for Breast Cancer Candidate Zacks +7.29%
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-12-19 12:00PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-11-19 08:48AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE
Jan-08-19 12:12PM  History Says Pump the Brakes on a Clovis Oncology Stock Rally Schaeffer's Investment Research +9.99%
Jan-07-19 12:37PM  Here's Why Clovis Oncology Rose as Much as 21.9% Today Motley Fool +18.48%
08:00AM  Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2018 Business Wire
Jan-02-19 04:05PM  Clovis Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire +7.96%
Dec-27-18 06:06PM  Immunomedics Enters Into Supply Deal for Breast Cancer Drug Zacks -5.07%
Dec-26-18 07:25AM  Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences What Drives Growth in Today's Competitive Landscape GlobeNewswire +9.47%
Dec-20-18 05:34PM  AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting Zacks
Dec-17-18 01:14PM  Activist Pushing Cancer Drugmaker Clovis to Pursue Sale Bloomberg -9.06%
Dec-16-18 03:07AM  Argentiere Capitals Returns, AUM and Holdings Insider Monkey
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-14-18 08:33AM  Do Options Traders Know Something About Clovis (CLVS) Stock We Don't? Zacks
Dec-13-18 12:46PM  CHMP Grants Positive Opinion for New Indication of Clovis Oncologys Rubraca® (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer Business Wire
Dec-11-18 12:42PM  Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate Benzinga
Dec-10-18 11:00AM  Biotech Stocks Beating the Market ACCESSWIRE
08:45AM  Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher Zacks
Dec-09-18 01:27AM  Should You Avoid Clovis Oncology Inc (CLVS)? Insider Monkey
Dec-08-18 05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPICKSCHEN THORLEFDirectorAug 16Buy5.678,60048,76258,176Aug 16 05:45 PM
SPICKSCHEN THORLEFDirectorAug 14Buy5.469,20050,23249,576Aug 15 04:12 PM
KLINGENSTEIN PAUL HDirectorJul 29Option Exercise0.2925,8627,50059,327Jul 31 04:24 PM
Rolfe LindseySee RemarksJun 20Sale14.701,72825,40221,591Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 20Sale14.7082912,186191,788Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 04Sale15.075778,695190,357Jun 06 04:48 PM
MUEHL DANIEL WSee RemarksJun 04Sale15.074536,8277,905Jun 06 04:46 PM
Gross Paul EdwardSee RemarksJun 04Sale15.074536,8274,001Jun 06 04:45 PM
Rolfe LindseySee RemarksJun 04Sale15.076559,87119,537Jun 06 04:45 PM
MUEHL DANIEL WSee RemarksMay 29Sale14.882714,0327,643May 31 05:01 PM
IVERS-READ GILLIAN CSee RemarksMar 20Sale26.1383021,688190,007Mar 21 05:00 PM
Rolfe LindseySee RemarksMar 20Sale26.131,72945,17919,224Mar 21 04:57 PM
BLAIR JAMES CDirectorMar 14Sale27.7917,056473,9860Mar 18 04:53 PM
Gross Paul EdwardSee RemarksMar 05Sale29.291,32538,8092,577Mar 06 04:47 PM
IVERS-READ GILLIAN CSee RemarksMar 05Sale29.291,61147,186187,507Mar 06 04:47 PM
Rolfe LindseySee RemarksMar 05Sale29.291,73150,70116,176Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksMar 05Sale29.291,29737,9896,177Mar 06 04:45 PM
MUEHL DANIEL WSee RemarksFeb 27Sale25.902666,8895,945Feb 28 06:25 PM
SPICKSCHEN THORLEFDirectorJan 03Option Exercise0.8832,75828,74040,376Jan 03 04:45 PM
Rolfe LindseySee RemarksDec 20Sale17.721,72830,62015,872Dec 26 09:00 AM
IVERS-READ GILLIAN CSee RemarksDec 20Sale17.7282914,690187,198Dec 26 09:00 AM
Rolfe LindseySee RemarksDec 04Sale21.232846,02914,162Dec 06 05:05 PM
MUEHL DANIEL WSee RemarksDec 04Sale21.231883,9915,664Dec 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksDec 04Sale21.232505,308186,152Dec 06 04:45 PM